Recent advancements in HIV research are showing promising results. The RIO trial, led by Imperial College London, assessed the impact of two long-acting immune therapies known as broadly neutralizing antibodies (bNAbs) among 68 people living with HIV. The trial results revealed that three-quarters of participants who received the bNAbs were able to control the virus while off their antiretroviral therapy over a 20-week period.
Drs. Marina Caskey and Michel Nussenzweig from Rockefeller University noted that these bNAbs significantly reduced the size of the HIV reservoir, even reaching undetectable levels in some participants. This breakthrough could open new avenues for HIV treatment, bringing us closer to achieving a cure.
